重度抑郁症(MDD)是一种神经精神疾病,由于其复杂的内表型,诊断和管理仍然具有挑战性。在这方面,循环microRNAs(cimiRNAs)作为生物标志物提供了巨大的潜力,并可能为MDD诊断提供新的见解。因此,我们系统回顾了文献,以探索有助于MDD诊断的各种cimiRNAs和潜在的分子通路.进行了全面的文献调查,从2012年到2021年1月使用四个数据库。在1004条记录中,访问了157份合格标准报告,和32份符合我们纳入标准的报告被考虑进行计算机内分析.这项研究确定了MDD患者中99个失调的cimiRNAs,选择在多个报告中发现的20个cimiRNA进行计算机内分析。KEGG通路分析表明ALS激活,MAPK,p53和P13K-Akt信号通路,而基因本体论分析表明,大多数蛋白质靶标与转录相关。此外,染色体位置分析显示,在3p22-p21、9q22.32和17q11.2附近,异常调节的cimiRNAs聚集,提示它们与主要参与MDD生理学的特定转录因子共调节.对转录因子位点的进一步分析揭示了HIF-1、REST、和TAL1在大多数cimiRNAs中。这些转录因子被提议靶向与MDD相关的基因,假设第一波cimiRNA失调可能引发第二波转录范围的变化,改变MDD影响细胞的蛋白质表达。总的来说,这篇系统综述提供了MDD中失调的cimiRNAs列表,特别是miR-24-3p,让7a-5p,miR-26a-5p,miR135a,miR-425-3p,miR-132、miR-124和miR-16-5p为最突出的cimiRNAs。然而,各种限制不允许我们对这些cimiRNAs的临床意义做出坚定的结论,这表明需要对单个血液区室进行更多的研究,以确定MDD中持续失调的cimiRNAs的生物标志物潜力,以及这些计算机内见解的治疗意义。
Major depressive disorder (MDD) is a neuropsychiatric disorder, which remains challenging to diagnose and manage due to its complex endophenotype. In this aspect, circulatory microRNAs (cimiRNAs) offer great potential as biomarkers and may provide new insights for MDD diagnosis. Therefore, we systemically reviewed the literature to explore various cimiRNAs contributing to MDD diagnosis and underlying molecular pathways. A comprehensive literature survey was conducted, employing four databases from 2012 to January 2021. Out of 1004 records, 157 reports were accessed for eligibility criteria, and 32 reports meeting our inclusion criteria were considered for in-silico analysis. This study identified 99 dysregulated cimiRNAs in MDD patients, out of which 20 cimiRNAs found in multiple reports were selected for in-silico analysis. KEGG pathway analysis indicated activation of ALS, MAPK, p53, and P13K-Akt signaling pathways, while gene ontology analysis demonstrated that most protein targets were associated with transcription. In addition, chromosomal location analysis showed clustering of dysregulated cimiRNAs at proximity 3p22-p21, 9q22.32, and 17q11.2, proposing their coregulation with specific transcription factors primarily involved in MDD physiology. Further analysis of transcription factor sites revealed the existence of HIF-1, REST, and TAL1 in most cimiRNAs. These transcription factors are proposed to target genes linked with MDD, hypothesizing that first-wave cimiRNA dysregulation may trigger the second wave of transcription-wide changes, altering the protein expressions of MDD-affected cells. Overall, this systematic
review presented a list of dysregulated cimiRNAs in MDD, notably miR-24-3p, let 7a-5p, miR-26a-5p, miR135a, miR-425-3p, miR-132, miR-124 and miR-16-5p as the most prominent cimiRNAs. However, various constraints did not permit us to make firm conclusions on the clinical significance of these cimiRNAs, suggesting the need for more research on single blood compartment to identify the biomarker potential of consistently dysregulated cimiRNAs in MDD, as well as the therapeutic implications of these in-silico insights.